PreveCeutical Medical Inc. (CNSX:PREV) Chairman and CEO Stephen Van Deventer joined Steve Darling from Proactive Investors to talk about the medical company that has recently filed two new patent applications for cyclic peptides and their use in pain management.
Van Deventer also talked about the company filing an application to a local hospital’s Human Ethics Committee to acquire human nasal mucosal tissue for the final phase of the cannabinoid-based, soluble gel.
Price: $0.04
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc named herein, including the promotion by the Company of PreveCeutical Medical Inc in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE
PreveCeutical (CNSX:PREV) Chief Research Officer Dr Harry Parekh joined Steve Darling from Proactive Investors Vancouver to talk about the companies progress in the development of their sol-gel. Parekh telling proactive the next step they are undertaking with human tissue. He also talked...
Prev article
